Here are three quick notes:
1. The poster presentations highlight data from the oliceridine program, which compares oliceridine to conventional opioid analgesics.
2. Oliceridine was designed to deliver an improved analgesic profile. It has been granted ‘Breakthrough Therapy’ designation by the FDA.
3. The presentations will include key data from the company’s phase 2b trial focusing on acute pain following abdominoplasty.
More articles on anesthesia:
8 anesthesiology groups named in Colorado Medicaid over-billing probe: 4 key notes
NAPA acquires Anesthesia Care Group: 3 things to know
Dr. John Brock-Utne releases book on clinical research quandaries: 3 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
